Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- ...

OBI Pharma has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) ...

VERAXA Biotech AG ( VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

Cidara Therapeutics shifted its focus from antifungal treatments to its proprietary Cloudbreak drug Fc conjugate platform.

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG(NAS ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...

Babies treated with antibiotics in the first few weeks are likely to show weaker immune responses to essential vaccines taken ...

The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation.

University of Edinburgh scientists have harnessed the power of AI in a new tool that promises to speed up analysis of data from gel electrophoresis ...

Small but powerful language adjustments represent a fundamental mindset shift in how educators approach engagement and ...